Medical devices behemoth Stryker agreed to buy Inari Medical for $4.9 billion. Inari stock catapulted Tuesday on the news.

Inari’s catalog includes the catheter-based FlowTriever and ClotTriever systems for mechanically removing blood clots in cases of pulmonary embolism and deep vein thrombosis, respectively.

Analysts' ratings for Inari Medical NARI over the last quarter ... Its product portfolio includes; ClotTriever, for the removal of the clot from peripheral blood vessels and treats patients ...

The deal for Inari bolsters Stryker's efforts to build out its offerings to treat a condition called venous thromboembolism, where a blood clot forms in a vein, and other vascular diseases. Under the ...

Inari has developed two minimally-invasive, novel catheter-based mechanical thrombectomy devices that are designed to remove large clots from large vessels and eliminate the need for thrombolytic ...

Inari Medical Inc (NASDAQ:NARI) makes medical devices to treat blot clots in veins and their main products are designed to remove clots from deep veins and pulmonary arteries without using clot ...

The deal for Inari bolsters Stryker’s efforts to build out its offerings to treat a condition called venous thromboembolism, where a blood clot forms in a vein, and other vascular diseases.